|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Overexpression of C-terminal binding protein-2 (CtBP2) has been noted to correlate with cancer metastasis in several human cancers including breast cancer.
|
24522810 |
2014 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein-2 (CtBP2) enhances cancer proliferation and metastasis.
|
28412731 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Finally, we demonstrate that CtBP1 and CtBP2 both have p53-dependent and -independent roles in suppressing the sensitivity of breast cancer cells to mechanistically diverse cancer chemotherapeutic agents.
|
20964627 |
2010 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Although its functions remain to be clarified in PCa cells, HNF1β and CtBP2 are associated with cancer cell proliferation, tumor progression, and castration-resistant disease.
|
24332637 |
2014 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
MDSCs triggered miRNA101 expression in cancer cells. miRNA101 subsequently repressesed the corepressor gene C-terminal binding protein-2 (CtBP2), and CtBP2 directly targeted stem cell core genes resulting in increased cancer cell stemness and increasing metastatic and tumorigenic potential.
|
24012420 |
2013 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of both CtBP2 and p16INK4A were significantly related to histological differentiation (P < 0.01 and P = 0.004, respectively) and metastasis (P = 0.046 and 0.047, respectively).
|
28412731 |
2017 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Our data revealed that the expression of CtBP1, but not CTBP2, was upregulated in 102 GC tissue samples compared with 98 noncancerous tissue samples, and the elevated expression level of CtBP1 was notably associated with distant metastasis.
|
31308691 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The aim of this study was to examine the effect of cyclase-associated protein 1 (CAP1) overexpression on CtBP2 expression and related mechanism in the metastasis of breast cancer.
|
24522810 |
2014 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, CtBP2 is overexpressed in GC and may accelerate GC tumorigenesis and metastasis, which could represent an independent prognostic marker and promising therapeutic target for GC.
|
28404932 |
2017 |
|
Neoplasm Metastasis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The results revealed that the expression of CtBP2, but not CtBP1, was upregulated in OS tissue samples and the elevated expression level of CtBP2 was notably associated with distant metastasis.
|
31214864 |
2019 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression.
|
25820824 |
2015 |
|
Tumor Progression
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
In the "CKP" mouse pancreatic ductal adenocarcinoma (PDAC) model driven by mutant K-Ras, Ctbp2 haploinsufficiency prolonged survival, abrogated peritoneal metastasis, and caused dramatic downregulation of c-Myc, a known critical dependency for TIC activity and tumor progression in PDAC.
|
31586042 |
2019 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In summary, the present studies revealed that the loss of CtBP2 constrained distant metastasis through the JAK1/Stat3 pathway in OS, suggesting that targeting CtBP2 may be a practical anti-tumor approach to prevent OS tumor progression.
|
31214864 |
2019 |
|
Tumor Progression
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
C-terminal binding protein‑2 (CtBP2) is a transcriptional co-repressor that is associated with tumorigenesis and tumor progression.
|
29658564 |
2018 |
|
Tumor Progression
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, silencing of CtBP2 markedly increased the apoptosis of PCa cells in vitro, and decreased the expression of IL-8, AT2R, CCND1 and MMP9 which are associated with cancer progression.
|
28677795 |
2017 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our investigations demonstrated that low-expression of CtBP2 could highly inhibit proliferation of prostate cancer by c-Myc induced signaling, suggesting that targeting CtBP2 may yield a viable anti-tumor strategy by restraining tumor progression in prostate cancer.
|
24835310 |
2014 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
|
24332637 |
2014 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Down-regulation of C-terminal binding protein 2 (CtBP2) inhibits proliferation, migration, and invasion of human SHSY5Y cells in vitro.
|
28179207 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CtBP2 was demonstrated to modulate cell migration and invasion via JAK1/Stat3 signaling pathway in fetal osteoblast cells.
|
31214864 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Meanwhile, CTBP2 silencing can rescued the phenotype changes induced by miR-338-5p inhibitor on cell proliferation and invasion in glioma.
|
28826173 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
C-terminal binding protein 2 (CtBP2) is a transcriptional co-repressor that promotes cancer cell migration and invasion by inhibiting multiple tumor suppressor genes that contribute to cell mobility and adhesion.
|
25686837 |
2015 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CTBP2 restoration overturned cell viability and invasion suppression mediated by NEAT1 knockdown or miR-129 overexpression.
|
29147064 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CtBP2 induced epithelial-to-mesenchymal transition (EMT) and repressed PTEN to increase proliferation rate, migration, and invasion in GC cells.
|
28404932 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
MDSCs triggered miRNA101 expression in cancer cells. miRNA101 subsequently repressesed the corepressor gene C-terminal binding protein-2 (CtBP2), and CtBP2 directly targeted stem cell core genes resulting in increased cancer cell stemness and increasing metastatic and tumorigenic potential.
|
24012420 |
2013 |